Diabetes drug metformin could boost myeloma treatment
NCT ID NCT02967276
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This phase 2 trial tests whether adding metformin — a common diabetes medication — to high-dose dexamethasone can improve outcomes for people with multiple myeloma that has returned or stopped responding to prior treatments. The study enrolls adults over 18 who have failed at least two previous lines of therapy. Participants take metformin daily along with high-dose dexamethasone for six cycles, and researchers measure how many patients achieve a complete, partial, or minimal response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- metformin and dexamethasone
- What this could lead to
- If it works, this could offer a new, affordable treatment option for patients with multiple myeloma that has stopped responding to standard therapies.
- What could go wrong
- This is a small, early-phase trial (28 people) with no placebo group, so results may not be definitive. Metformin can cause gastrointestinal side effects, and high-dose dexamethasone has significant risks like infection and high blood sugar.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hemocentro - Hospital de Clínicas - State University of Campinas (UNICAMP)
Campinas, São Paulo, Brazil
-
UOPECCAN - Hospital do Câncer de Cascavel
Cascavel, Paraná, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- A One-Shot gene therapy could take on incurable blood cancer
- New PET tracer could sharpen diagnosis of blood cancers
- Web tool aims to empower rare cancer patients in genomic choices
- Experimental drug HDP-101 targets Hard-to-Treat myeloma